Metformin as an Upstream Therapy in Atrial Fibrillation
| Status: | Terminated |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2018 |
| Start Date: | April 11, 2017 |
| End Date: | July 10, 2018 |
The purpose of this study is to see if the study drug metformin will help patients who are
overweight and have atrial fibrillation. This study aims to see if metformin helps patients
stay in normal sinus rhythm after a catheter ablation.
Metformin is investigational for use in patients with atrial fibrillation. Metformin is
approved by the Food and Drug Administration (FDA) for use in patients with type 2 Diabetes
Mellitus. Metformin is used with a proper diet and exercise program to control high blood
sugar, and has been shown to help people lose weight. This study aims to look at the effects
of metformin on weight loss and heart rhythm in patients with atrial fibrillation.
overweight and have atrial fibrillation. This study aims to see if metformin helps patients
stay in normal sinus rhythm after a catheter ablation.
Metformin is investigational for use in patients with atrial fibrillation. Metformin is
approved by the Food and Drug Administration (FDA) for use in patients with type 2 Diabetes
Mellitus. Metformin is used with a proper diet and exercise program to control high blood
sugar, and has been shown to help people lose weight. This study aims to look at the effects
of metformin on weight loss and heart rhythm in patients with atrial fibrillation.
Inclusion Criteria:
- All individuals diagnosed with Atrial Fibrillation and choosing to undergo a rhythm
control strategy at Robert Packer Hospital with a BMI ≥ 27 will be eligible for the
study. All subjects must be able to understand and willing to sign a written informed
consent document.
Exclusion Criteria:
- Individuals who are already taking metformin or other antidiabetic medications
including insulin, have a diagnosis of diabetes, have a known allergy or FDA-labeled
contraindication to taking metformin, eGFR below 30 mL/min per 1.73 m2 or other
clinical diagnosis of advanced renal disease,, have acute or chronic metabolic
acidosis (serum bicarbonate <22 mEq/L), have a history of significant alcohol use (>2
drinks/day on average), have a history of hepatic dysfunction (serum bilirubin 1.5X
greater than the upper limit of normal), have a history of New York Heart Association
(NYHA) Class III or IV heart failure, or are pregnant will be excluded from the trial.
We found this trial at
1
site
Click here to add this to my saved trials
